Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: The role of the aromatic ring

Drug Safety

Volumn 31, Issue 8, 2008, Pages 695-702

  Handoko, Kim B ^a,b   Van Puijenbroek, Eugène P ^c   Bijl, Annemarie H ^c   Hermens, Walter A J J ^b   Zwart Van Rijkom, Jeannette E F ^d   Hekster, Yechiel A ^e   Egberts, Toine C G ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Ziekenhuisapotheek Noordoost Brabant   (Netherlands)

^c NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse drug reactions; Antiepileptic drugs, adverse reactions; Drug hypersensitivity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; IMMUNOGLOBULIN E; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADULT; ARTICLE; CELLULAR IMMUNITY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; ERYTHEMA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE COMPLEX DISEASE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PAPULAR RASH; PRIORITY JOURNAL; PUSTULE; RASH; SKIN ALLERGY; SKIN MANIFESTATION; STRUCTURE ANALYSIS; T LYMPHOCYTE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTICONVULSANTS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; YOUNG ADULT;

EID: 47649090963     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831080-00006     Document Type: Article

References (31)

1. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48 (7): 1223-44
2. Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000; 23 (1): 35-56
3. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39 Suppl. 7: S22-6
4. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64 (7): 1134-8
5. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155 (21): 2285-90
6. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21 (6): 489-501
7. Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in children. Ann Pharmacother 2001; 35 (5): 533-8
8. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007; 68 (20): 1701-9
9. Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf 2000; 22 (6): 415-23
10. Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316 (7140): 1295-8
11. Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol 2003; 111 (2 Suppl.): S548-59
12. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3 (4): 367-77
13. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63 (3): 732-41
14. Naisbitt DJ, Williams DP, Pirmohamed M, et al. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 2001; 1 (4): 317-25
15. Spielberg SP, Gordon GB, Blake DA, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981; 217 (2): 386-9
16. van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 2003; 26 (5): 293-301
17. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20 (2): 109-17
18. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachman PJ, editors. Clinical aspects of immunology. Oxford: Blackwell Scientific Publications, 1975: 761-81
19. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139 (8): 683-93
20. Castell JV. Allergic hepatitis: a drug-mediated organ-specific immune reaction. Clin Exp Allergy 1998; 28 Suppl. 4: 13-9
21. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11 (1): 3-10
22. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11 (9): 969-88
23. Jerina DM, Daly JW. Arene oxides: a new aspect of drug metabolism. Science 1974; 185 (151): 573-82
24. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl. 7: S8-16
25. Klassen BD, Sadler RM. Induction of hypersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug. Epilepsia 2001; 42 (3): 433-5
26. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82 (6): 1826-32
27. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111 (6): 1393-403
28. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48 (5): 1015-8
29. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29 (5): 385-96
30. Smith CC, Bennett PM, Pearce HM, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996; 42 (4): 423-9
31. Strom BL. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons, 2005